Researchers at The University of Texas MD Anderson Cancer Center are investigating psilocybin-assisted psychotherapy as a clinical tool to treat the psychological trauma and existential distress associated with head and neck cancer. According to Moran Amit, MD, PhD, a surgical oncologist leading the trials, the goal is to help patients cope with the significant functional and social isolation caused by the disease and its treatments.
How does cancer interact with the nervous system?
Cancer cells have the biological capacity to hijack the nervous system to facilitate their own growth. In a 2020 study published in the journal Nature, Amit and his colleagues demonstrated that tumors modify neural pathways in ways that benefit the cancer. This discovery prompted researchers to investigate whether the nervous system could be “hijacked back” to combat the disease. While exploring potential compounds to intervene, Amit’s team identified tryptamines—a family of drugs that includes psilocybin—as a viable area for clinical research, according to his findings at MD Anderson.
Head and neck cancer patients face one of the highest suicide rates among all oncology populations, according to research published in Nature Communications. The visible nature of the disease often leads to profound social isolation and trauma.
What are the primary goals of the MD Anderson trials?
The MD Anderson trials focus on two distinct populations: patients undergoing treatment with curative intent and those who are cancer-free but still struggling with the psychological aftermath of their diagnosis. Unlike previous psychedelic research, which primarily targeted terminally ill patients, Amit’s team is gathering data on how to support those living with cancer as a chronic condition. The protocol aims to transition patients back to their pre-cancer mental state, addressing the existential crises that often accompany long-term cancer management, according to clinical trial documentation.
How is psilocybin-assisted psychotherapy administered?
The treatment follows a structured, non-medicalized protocol designed to ensure patient safety. According to Amit, each patient undergoes preparation sessions with therapists, followed by two dosing days. During these days, two therapists remain present in a specially designed, comfortable room to monitor the patient. Integration sessions occur both immediately after dosing and approximately one week later. This condensed, two-to-three-week treatment package is intended to provide long-term therapeutic benefits in a short timeframe.
Pro Tip: The Importance of “Set and Setting”
Clinical efficacy depends heavily on the “set and setting,” according to Amit. The “set” refers to the patient’s mindset, which is addressed during preparatory sessions, while the “setting” involves the physical environment and the presence of professional monitors to ensure safety during the experience.
What are the next steps for psychedelic oncology research?
While the team continues to monitor safety and feasibility, they are currently evaluating whether psilocybin can mitigate the physical toxicities associated with cancer treatment. Amit notes that future trials may explore the potential for these compounds to address neurotoxicity caused by chemotherapy and radiation. The team is currently working to determine how to safely administer these therapies to patients with complex physical limitations, such as those who have difficulty speaking or swallowing due to their cancer, as stated in recent trial updates.
Frequently Asked Questions
Is psilocybin-assisted therapy safe for patients on chemotherapy?
Safety is the primary focus of the ongoing MD Anderson trials. Researchers are actively studying how psilocybin interacts with standard cancer treatments, including radiation and chemotherapy, to ensure the therapy remains safe for patients with high medical complexity.
How does this differ from traditional therapy?
According to feedback cited by Amit, patients report that the condensed, two-to-three-week psilocybin-assisted protocol provides a transformative experience that can achieve results similar to years of traditional talk therapy.
Are these treatments available to the public?
These protocols are currently being conducted within clinical trials at MD Anderson. Patients interested in participating should consult their oncology team or review active listings on ClinicalTrials.gov to see if they meet the criteria for enrollment.
Have you or a loved one navigated the psychological challenges of cancer treatment? Share your experiences in the comments below or subscribe to our newsletter for the latest updates on oncology research and mental health innovations.
